A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib
Status:
Completed
Trial end date:
2019-04-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, parallel group, single dose study to investigate the effect of
moderate or severe hepatic impairment on the PK of glasdegib, compared to subjects with
normal hepatic function.